Takeover Possibility
Is Fitbit Ripe for a Takeover?
FIT indeed has much to prove, the early 2015 euphoria is gone, and most growth investors have moved on.
Pseudo QE, Essent Group's Essence and Datadog-Cisco Intrique: Market Recon
Plus, defense contractors remain stocks to own as geopolitical risk isn't going away.
M&A Appetite in Pharma Has Proved Potent: Chart of the Day
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Do Activists Have an Answer at Bed Bath & Beyond?
Is a turnaround even possible anymore?
Can Saggy Fitbit Regain Its Shape? This Value Investor Hopes So
Shares of the maker of health and fitness devices are near their all-time low, but buying now could pay off down the road.
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land
These two firms have successful drugs and could make nice additions for larger companies.
2 Small Biotechs With Sagging Shares but Promising Prospects
The stocks of these two developmental concerns have slid recently, but there are reasons to believe they will improve.
Why an Etsy, Pinterest Partnership Makes Sense
If Pinterest is pinning its hopes of profitability on e-commerce, Etsy would be an excellent choice.
It's Tough to Milk Any Profits From Dean Foods
Rumors of a potential company sale gave its shares a lift on Monday, but the stock remains extremely depressed as the dairy producer wallows in red ink.